65,437 trials
Hyperlipidemia · Mixed Dyslipidemia
Primary: Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12 — 30.1; 9.4 percent change — p=<0.001
Growth Hormone Therapy · Infant, Very Low Birth Weight
Primary: Change in Height Standard Deviation Score (SDS) After 1 Year — 1.099; 0.108 centimeters — p=<0.001
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec) — 64.9; 69.7 Percentage of FVT episodes…
Eyelashes
Primary: Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16 — 5.1; 2.1; 14.6; 7.8…
Hypertriglyceridemia
Primary: Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period — -40.2; -33.7 percent change…
Influenza
Primary: Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 2 — 47; 40 Participants
Vulvovaginal Candidiasis
Primary: Candida Culture Free After Maintenance Therapy — 18; 19; 9 participants
Postoperative Pain · Wisdom Tooth
Primary: Number of Patients Needing Rescue Medication — 32; 29 Participants
Herpes Simplex
Primary: Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study. — 0; 2; 1; 2 participants
Carotid Artery Stenosis
Primary: Composite Major Adverse Event (MAE) Rate — 0; 5; 2; 2 participants — p=0.002
Infections, Rotavirus
Primary: Number of Subjects Reporting Any Serious Adverse Events (SAEs). — 34; 23 subjects
Type 2 Diabetes
Primary: Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24 — -0.47; 0.23 Percent — p=<0.001
Hepatitis B
Primary: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations — 87.6; 43.8; 143.4; 34.4 mIU/mL
Essential Hypertension
Primary: Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy) — 38 Participants
Meningococcal Infections · Meningitis
Primary: Percentage of Participants With ≥ 4-Fold Rise in Antibody Titers — 85; 61; 61; 76 Percentage of participants